BEUDAMED
    FDA Adverse Event Injury Summary report: N

    ZILVER PTX 35 DRUG-ELUTING STENT

    MDR report key: 11937776 · Received June 4, 2021

    Report

    Report Number
    3001845648-2021-00434
    Event Type
    Injury
    Date Received
    June 4, 2021
    Report Date
    January 28, 2022
    Manufacturer
    COOK IRELAND LTD
    Product Code
    NIU
    Adverse Event
    Yes
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    PMA/510(K) #: P100022/S027 OR P100022/S014. DEVICE EVALUATION: THE ZISV6 DEVICE OF UNKNOWN LOT NUMBER INVOLVED IN THIS COMPLAINT WAS IMPLANTED IN THE PATIENT AND WAS NOT AVAILABLE FOR EVALUATION. WITH THE INFORMATION PROVIDED, A DOCUMENT BASED INVESTIGATION WAS CONDUCTED. LAB EVALUATION ¿ N/A. DOCUMENT REVIEW: AS THE RPN AND LOT NUMBER OF THE COMPLAINT STENTS ARE UNKNOWN, A REVIEW OF THE RELEVANT MANUFACTURING RECORDS CANNOT BE CONDUCTED. HOWEVER, PRIOR TO DISTRIBUTION ZISV6 DEVICES ARE SUBJECTED TO A VISUAL INSPECTION AND FUNCTIONAL CHECKS TO ENSURE DEVICE INTEGRITY. THESE INSPECTIONS AND FUNCTIONAL CHECKS ARE OUTLINED IN INTERNAL PROCEDURES IN PLACE AT CIRL. IT SHOULD BE NOTED THAT RESTENOSIS OF THE STENTED ARTERY IS LISTED AS A KNOWN POTENTIAL ADVERSE EVENT WITHIN THE INSTRUCTIONS FOR USE (IFU0117-5). THERE IS NO EVIDENCE TO SUGGEST THE USER DID NOT FOLLOW THE IFU. IMAGE REVIEW ¿ N/A. ROOT CAUSE REVIEW A DEFINITIVE ROOT CAUSE COULD NOT BE DETERMINED FROM THE AVAILABLE INFORMATION. A POSSIBLE ROOT CAUSE COULD BE ATTRIBUTED TO PATIENT PRE-EXISTING/UNDERLYING CONDITIONS. FROM THE LITERATURE ARTICLE IT IS KNOWN THAT PATIENT PRE-EXISTING CONDITIONS INCLUDED SCLERODERMA, INTERMITTENT CLAUDICATION OF BOTH LOWER LIMBS AND BILATERAL LOW ANKLE-BRACHIAL INDEX. RESTENOSIS OF THE STENTED ARTERY IS ALSO LISTED AS A KNOWN POTENTIAL ADVERSE EVENT WITHIN THE IFU AND IS A COMMON ADVERSE EVENT OF ENDOVASCULAR PROCEDURES THAT CAN BE CAUSED BY INJURY TO THE VESSEL (E.G. DURING PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) AND/OR STENTING). VESSEL INJURY PROVOKES AN INFLAMMATORY RESPONSE THAT LEADS TO OR AMPLIFIES THE RESTENOSIS PROCESS. IT MAY BE NOTED THAT THE SURFACE OF THE ZILVER PTX STENT IS COATED WITH THE DRUG PACLITAXEL TO HELP PREVENT SUBSEQUENT RESTENOSIS OF THE ARTERY. SUMMARY COMPLAINT IS CONFIRMED BASED ON CUSTOMER TESTIMONY. THE PATIENT OUTCOME IS UNKNOWN. COMPLAINTS OF THIS NATURE WILL CONTINUE TO BE MONITORED FOR POTENTIAL EMERGING TRENDS.

    Description of Event or Problem · 0

    SUPPLEMENTAL REPORT IS BEING SUBMITTED DUE TO THE COMPLETION OF THE INVESTIGATION.

    Additional Manufacturer Narrative · 1

    EXACT RPN IS UNKNOWN PMA/510(K) #: P100022/S027 OR P100022/S014. INVESTIGATION IS STILL PENDING, A FOLLOW UP MDR WILL BE SUBMITTED TO INCLUDE THE INVESTIGATION CONCLUSIONS.

    Description of Event or Problem · 1

    THE TITLE IS ¿THE CASE TREATED WITH EXCIMER LASER FOR TANDEM LESIONS INCLUDING REPEATED IN-STENT RESTENOSIS (RE-RESTENOSIS) OF DES IMPLANTED IN A SFA¿. THE PATIENT IS A (B)(6) YEAR-OLD FEMALE WHO HAS BEEN VISITING OUR HOSPITAL DUE TO SCLERODERMA. INTERMITTENT CLAUDICATION OF BOTH LOWER LIMBS AND BILATERAL LOW ABI HAD BEEN OBSERVED SINCE 2016, AND ZILVER PTX WAS IMPLANTED IN THE RIGHT SFA-CTO IN AUGUST 2018. INTERMITTENT CLAUDICATION RECURRED FROM APRIL 2019, AND ISR WAS OBSERVED IN THE RIGHT SFA, AND POBA WAS PERFORMED. IN OCTOBER 2020, THE RIGHT LOWER EXTREMITY BECAME CLI, AND ANGIOGRAPHY REVEALED RE-RESTENOSIS IN THE STENT, AS WELL AS NEW LESIONS IN THE PROXIMAL AND PROGRESSION OF CALCIFIED NODULES THAT HAD PREVIOUSLY FAILED TO DILATE. WE REPORT THE CASE BECAUSE WE PERFORMED TREATMENT BY USING EXCIMER LASER MAINLY ISR.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    838469 ZILVER PTX 35 DRUG-ELUTING STENT NIU STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING NIU COOK IRELAND LTD

    Patients

    Seq Age Sex Outcome Treatment
    1 69 YR Female Required Intervention